As with many chronic and often deadly diseases, an ounce of prevention can be worth a ton of cure. It's a breakthrough drug ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

In a bold step toward global health justice, Ugandan biotech company DEI BioPharma has announced it will begin manufacturing ...

A newly approved HIV medication provides near-total protection against infection with just two injections a year. It's called Lenacapavir. But the high price of the drug could limit its reach.

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

The drug is coming at a time when several studies aimed at finding an HIV cure or vaccine failed to yield expected results, even as the world races to end HIV/AIDs as a public health threat by 2030.